Background: Acid sphingomyelinase deficiency (ASMD) is a rare lysosomal disorder defined by progressive storage of sphingomyelin, leading to hepatosplenomegaly, dyslipidemia, pulmonary restrictive insufficiency, hematological abnormalities and variable CNS involvement. Groundbreaking enzyme replacement therapy with Olipudase-alfa has reshaped the face of this disease. Treatment has been available in Romania since 2024 and is already producing life-changing results.
Case Series Summary: The authors present enzyme replacement therapy results in 5 cases of ASMD diagnosed and treated in Grigore Alexandrescu Children Hospital in Bucharest.
Case 1: 17 years 3 months old boy, no sphingomyelinase activity, homozygous c.1177T>G, started treatment in August 2024, currently at 37th dose. Until 2 months ago, hepatosplenomegaly significantly decreased (June 2024: liver 2213 cm3, spleen 1856.3 cm3; March 2026: liver 763.2 cm3, spleen 1490.7 cm3). Pancytopenia resolved, liver cytolysis and dyslipidemia improved. He reached full pubertal development and had an increase in height by 9 cm in the first 14 months of treatment, then 10 cm in the past year. At his last follow-up, thrombocytopenia and enlarging liver and spleen were noticed; development of anti-enzyme antibodies is now taken into consideration.
Case 2: 8 years 6 months old boy, low sphingomyelinase activity, homozygous c.1177T>G, started treatment in October 2024, currently at 34th dose. Organomegaly significantly decreased (September 2024: liver 545 cm3, spleen 667 cm3; March 2026: liver 405 cm3, spleen 213 cm3), he increased in height by 15 cm in the past 2 years. Anemia resolved in one month, liver enzymes normalized.
Case 3: 16 years old girl, no sphingomyelinase activity, homozygous c.1177T>A-IN, with severe chronic ataxia, started treatment in November 2025, currently at 14th dose. Organomegaly, especially the spleen significantly decreased (July 2025: liver 1032 cm3, spleen 1410 cm3; March 2026: liver 939 cm3, spleen 642 cm3). Only mild thrombocytopenia persists.
Case 4: 13 years 6 months old girl (cousin of case 3), no sphingomyelinase activity, homozygous c.1177T>G, with progressive ataxic syndrome, started treatment in December 2025, now at 13th dose. She exhibits now only mild leucopenia, no cytolysis, no dyslipidemia. Organ enlargement started to decrease, especially the spleen (July 2025: liver 1128 cm3, spleen 1624 cm3; March 2026: liver 1104 cm3, spleen 798 cm3).
Case 5: 11 years 2 months old boy (brother of case 4), no sphingomyelinase activity, homozygous c.1177T>G, started treatment in December 2025, now at 13th dose. Lab findings are within normal range. Hepatomegaly remains, but splenomegaly is decreasing (July 2025: spleen 1375 cm3; March 2026: spleen 1093 cm3).
Cases 2 to 5 presented mild post-therapy hyperamylasemia, which has since resolved. No other adverse effects of enzyme infusions were noted so far.
Learning points discussion: New and effective therapies for rare disorders fully deserve the spotlight nowadays. Treatment of ASMD has taken a radical turn. Early diagnosis followed by prompt initiation of ERT substantially contributes to improving patient outcomes and overall well-being.

